



Eligibility Criteria

The National Institute for Health and Clinical Excellence (NICE) has recommended that **all psoriasis patients** in the UK should be registered with us. The following is our eligibility criteria:



**CHRONIC PLAQUE OR
GENERALISED
PUSTULAR PSORIASIS**



**WRITTEN
INFORMED CONSENT**



**UNDER CARE OF A
DERMATOLOGIST**

Treatments

Patients must be **starting** or **switching to** one of these drugs, **for treatment of their psoriasis**, in the **last 6 months** to be eligible for our conventional, biologic or small molecule cohorts:

CONVENTIONAL

- ✓ Acitretin
- ✓ Ciclosporin
- ✓ Fumaric acid esters
- ✓ Hydroxycarbamide
- ✓ Methotrexate
- ✓ Systemic oral PUVA

BIOLOGIC

- ✓ Bimzelx (bimekizumab)
- ✓ Cimzia (certolizumab pegol)
- ✓ Cosentyx (secukinumab)
- ✓ Ilumetri (tildrakizumab)
- ✓ Kyntheum (brodalumab)
- ✓ Skyrizi (risankizumab)
- ✓ Taltz (ixekizumab)
- ✓ Tremfya (guselkumab)

SMALL MOLECULE

- ✓ Skilarence (dimethyl fumarate)

PASI & DLQI

Conventional patients must have a **PASI of 10 or more** and a **DLQI of 11 or more** (unless switching between conventional therapies). There is no minimum score for biologic or small molecule patients (but we still require a PASI and DLQI).

Patients entering either the small molecule or conventional cohorts must be **naive to biologic therapy**.

Paediatric Patients

If the patient is **under the age of 16 at the time of consent**, and starting **systemic treatment for psoriasis**, the patient will be eligible for BADBIR. Conventional patients **do not** need to meet the DLQI score criteria.



Tel: 0161 306 1896



Email: badbir@manchester.ac.uk



Web: badbir.org